Second Affiliated Hospital of Harbin Medical University
哈尔滨医科大学附属第二医院
Listed for 23 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Second Affiliated Hospital of Harbin Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatocellular carcinoma肝细胞癌49 papers led
- Stomach cancer胃癌35 papers led
- Lung cancer肺癌59 papers led
- Pancreatic cancer胰腺癌11 papers led
- Breast cancer乳腺癌48 papers led
- Glioma胶质瘤31 papers led
- Osteosarcoma骨肉瘤12 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤1 paper led
- Multiple myeloma多发性骨髓瘤6 papers led
- Lymphoma淋巴瘤2 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病1 paper led
- Myasthenia gravis重症肌无力8 papers led
- Coronary heart disease冠心病52 papers led2 open trials led
- Congenital heart disease先天性心脏病4 papers led
- Hepatic echinococcosis肝包虫病0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化11 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
- Fabry disease法布雷病0 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病3 papers led
- Congenital diaphragmatic hernia先天性膈疝0 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 49 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Harbin for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led49
- Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis.
- Advancements in locoregional therapy for advanced hepatocellular carcinoma: Emerging perspectives on combined treatment strategies.
- Exploring extrahepatic metastasis of hepatocellular carcinoma based on methylation driver genes and establishing a prognostic model for hepatocellular carcinoma.
- SIRT4 is associated with microvascular infiltration, immune cell infiltration, and epithelial mesenchymal transition in hepatocellular carcinoma.
- Disulfidptosis-related genes RPN1 inhibits the progression of hepatocellular carcinoma by regulating cell cycle, may be a new therapeutic targets.
- Celecoxib as a potential treatment for hepatocellular carcinoma in populations exposed to high PFAS levels.
- Exploring the mechanism of Naringenin in the treatment of hepatocellular carcinoma based on mRNA sequencing and experimental validation.
- Tumor-resident Malassezia can promote hepatocellular carcinoma development by downregulating bile acid synthesis and modulating tumor microenvironment.
- The resistance to anoikis, mediated by Spp1, and the evasion of immune surveillance facilitate the invasion and metastasis of hepatocellular carcinoma.
- Peripheral T-cell subsets in radiofrequency ablation for tumors from different origins.
- The Wnt signaling pathway in hepatocellular carcinoma: Regulatory mechanisms and therapeutic prospects.
- NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma.
- Neutrophil extracellular traps promote immune escape in hepatocellular carcinoma by up-regulating CD73 through Notch2.
- ANGPTL4 Stabilizes Bone Morphogenetic Protein 7 Through Deubiquitination and Promotes HCC Proliferation via the SMAD/MAPK Pathway.
- Angiopoietin-Related Protein 4-Transcript 3 Increases the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells and Inhibits Apoptosis.
- Effect of Deletion of ANGPTL4 Gene on Viability, Migration and Invasion Ability and Apoptosis of Hepatocellular Carcinoma Cells.
- Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
- Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
- Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.
- Construction and validation of prognostic signature for transcription factors regulating T cell exhaustion in hepatocellular carcinoma.
- Tumor-Targeted CO Nanodelivery System Design and Therapy for Hepatocellular Carcinoma.
- GABPA-Mediated Expression of HPN-AS1 Facilitates Cell Apoptosis and Inhibits Cell Proliferation in Hepatocellular Carcinoma by Promoting eIF4A3 Degradation.
- Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.
- Efficacy and Interpretability Analysis of Noninvasive Imaging Based on Computed Tomography in Patients with Hepatocellular Carcinoma After Initial Transarterial Chemoembolization.
- Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma.
- Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
- An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients.
- Deciphering essential druggable genes reveals potential immune-inflammatory axis in hepatocellular carcinoma.
- Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion.
- A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.
- The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC.
- Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study.
- Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression.
- Clathrin light chain A-enriched small extracellular vesicles remodel microvascular niche to induce hepatocellular carcinoma metastasis.
- Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients.
- Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.
- Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.
- CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.
- Reprogramming of central carbon metabolism in hepatocellular carcinoma.
- Targeting uridine-cytidine kinase 2 induced cell cycle arrest through dual mechanism and could improve the immune response of hepatocellular carcinoma.
- Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study.
- The Role of ANGPTL Gene Family Members in Hepatocellular Carcinoma.
- Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation.
- Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value.
- The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.
- Preparation of Poly[lactic-co-glycolic] Acid Nanospheres and Its Role in Hepatoma Cells.
- Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome.
- LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis.
- Cyclin B1 acts as a tumor microenvironment-related cancer promoter and prognostic biomarker in hepatocellular carcinoma.
Cancer
Stomach cancer
胃癌Led 35 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Harbin for stomach cancer211 hospitals in China for stomach cancer
No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led35
- Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.
- Effect of sodium-reduced potassium-enriched salt substitutes on stomach cancer: the Salt Substitute and Stroke Study (SSaSS).
- Investigating the dysregulation of genes associated with glucose and lipid metabolism in gastric cancer and their influence on immunity and prognosis.
- MEF2A, a gene associated with mitochondrial biogenesis, promotes drug resistance in gastric cancer.
- Gastric cancer-derived exosomal miR-196a-5p remodels the pre-metastatic niche for peritoneal dissemination.
- Magnetic anchors with line-guided endoscopic full-thickness resection for gastric submucosal tumors.
- Molecular Mechanisms of Neutrophil Extracellular Traps in Promoting Gastric Cancer Epithelial-Mesenchymal Transition Through SERPINE-1 Expression.
- Artificial Intelligence-Guided Identification of IGFBP7 as a Critical Indicator in Lactic Metabolism Determines Immunotherapy Response in Stomach Adenocarcinoma.
- Calcium overload via PVT1 reprograms neutrophil fate and constrains gastric cancer progression.
- Reprogramming of hsa_circ_0008719 and its target miR-3615 induced by TOB1 in exosomes of gastric cancer cells: a contribution to inhibit gastric cancer progression.
- TOB1 inhibits the gastric cancer progression by focal adhesion pathway and ERK pathway based on transcriptional and metabolic sequencing.
- Expression, DNA methylation pattern and transcription factor EPB41L3 in gastric cancer: a study of 262 cases.
- GDF15 enhances anoikis resistance and metastasis of gastric cancer through protective autophagy.
- TOB1 modulates neutrophil phenotypes to influence gastric cancer progression and immunotherapy efficacy.
- Application of Computer-Assisted Endoscopic Ultrasonography Based on Texture Features in Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Mesenchymal Tumors.
- MIEN1 on the 17q12 amplicon facilitates the malignant behaviors of gastric cancer via activating IL-6/JAK2/STAT3 pathway.
- Bromodomain containing 4 inhibition combats gastric precancerous lesions via modulating macrophage polarization.
- Neutrophil extracellular traps promote angiogenesis in gastric cancer.
- Effect of NETs/COX-2 pathway on immune microenvironment and metastasis in gastric cancer.
- Identification of lactylation related model to predict prognostic, tumor infiltrating immunocytes and response of immunotherapy in gastric cancer.
- Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.
- Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.
- The Overexpression of TOB1 Induces Autophagy in Gastric Cancer Cells by Secreting Exosomes.
- Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker.
- Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer.
- The promoter methylation drives down-regulation mode of HIC1 in gastric cancer, its molecular characteristics and downstream functional pathways.
- The Application Value of ceMDCT in the Diagnosis of Gastric Cancer Extramural Vascular Invasion and Its Influencing Factors.
- The functional variant in promoter of OVCA1 was associated with the risk of gastric cancer in the northeast Chinese Han population.
- Involvement of TOB1 on autophagy in gastric cancer AGS cells via decreasing the activation of AKT/mTOR signaling pathway.
- Neutrophil extracellular traps participate in the development of cancer-associated thrombosis in patients with gastric cancer.
- The rs9953490 polymorphism of DAL-1 gene is associated with gastric cancer risk in the Han population in Northeast China.
- Neutrophil extracellular traps promote gastric cancer metastasis by inducing epithelial‑mesenchymal transition.
- Anxiety and depression in recurrent gastric cancer: Their prevalence and independent risk factors analyses.
- Reminiscence therapy exhibits alleviation of anxiety and improvement of life quality in postoperative gastric cancer patients: A randomized, controlled study.
- ADAMTS12 acts as a tumor microenvironment related cancer promoter in gastric cancer.
Cancer
Lung cancer
肺癌Led 59 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Harbin for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led59
- Non-invasive Prediction of Lymph Node Metastasis in NSCLC Using Clinical, Radiomics, and Deep Learning Features From 18F-FDG PET/CT Based on Interpretable Machine Learning.
- Multimodal Positron Emission Tomography/Computed Tomography Radiomics Combined with a Clinical Model for Preoperative Prediction of Invasive Pulmonary Adenocarcinoma in Ground-Glass Nodules.
- Development and validation of machine learning models for early diagnosis and prognosis of lung adenocarcinoma using miRNA expression profiles.
- Immunoinfiltration Analysis of Mitochondrial Damage-Related Genes in Lung Adenocarcinoma and Construction of a Classification and Prognostic Model Integrated With WGCNA and Machine Learning Algorithms.
- Precise Molecular Subtyping Reveals Heterogeneity of Lung Adenocarcinoma Based on DNA Methylation.
- MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis.
- Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis.
- Gut microbiota and metabolite features in NSCLC nude mouse models of subcutaneous tumor and leptomeningeal metastasis: a microbiome-metabolome combined analysis.
- Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023.
- From central to peripheral: a novel robotic approach for lobectomy in patients with incomplete pulmonary fissures.
- Faster, safer, better recovery: a modified robotic-assisted segmentectomy versus conventional approaches in early stage lung cancer.
- Anti-tumor effects and mechanism of the histone demethylase inhibitor GSK-J4 in non-small cell lung cancer cells.
- Lactic acid promotes non-small cell lung cancer progression by down-regulating hexokinase 1 via histone lactylation: A Mendelian randomization study.
- A multilevel genomic approach to uncover causal connections between CPFE and lung cancer subtypes: A two-sample Mendelian randomization study.
- Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study).
- Prospective study of dual-phase 99mTc-MIBI SPECT/CT nomogram for differentiating non-small cell lung cancer from benign pulmonary lesions.
- Comprehensive analysis of PPP4C's impact on prognosis, immune microenvironment, and immunotherapy response in lung adenocarcinoma using single-cell sequencing and multi-omics.
- SLC12A8 promotes the migration and invasion of non-small cell lung cancer (NSCLC) cells.
- Combination of arsenic trioxide and apatinib synergistically inhibits small cell lung cancer by down-regulating VEGFR2/mTOR and Akt/c-Myc signaling pathway via GRB10.
- Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
- Identification of a potential sialylation-related pattern for the prediction of prognosis and immunotherapy response in small cell lung cancer.
- Predicting invasiveness of ground-glass nodules in lung adenocarcinoma: based on preoperative 18 F-fluorodeoxyglucose PET/computed tomography and high-resolution computed tomography.
- Identifying crucial lncRNAs and mRNAs in hypoxia-induced A549 lung cancer cells and investigating their underlying mechanisms via high-throughput sequencing.
- Development and validation of machine learning models for diagnosis and prognosis of lung adenocarcinoma, and immune infiltration analysis.
- Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.
- Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma.
- A novel single-docking direction of the robotic-assisted left upper lobectomy.
- Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer.
- Development and validation of an artificial intelligence prediction model and a survival risk stratification for lung metastasis in colorectal cancer from highly imbalanced data: A multicenter retrospective study.
- m6A-mediated lncRNA NEAT1 plays an oncogenic role in non-small cell lung cancer by upregulating the HMGA1 expression through binding miR-361-3p.
- An anoikis-based gene signature for predicting prognosis in malignant pleural mesothelioma and revealing immune infiltration.
- Development and validation of a nomogram for predicting overall survival of resected N2 non-small cell lung cancer patients undergoing neoadjuvant radiotherapy.
- Robot-assisted segmentectomy with improved modified inflation-deflation combined with the intravenous indocyanine green method.
- Value of preoperative 18F-FDG PET/CT and HRCT in predicting the differentiation degree of lung adenocarcinoma dominated by solid density.
- Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma.
- LncRNA RP11-58O9.2 predicts poor prognosis and promotes progression of non-small cell lung cancer.
- Comparison of tumor and two types of paratumoral tissues highlighted epigenetic regulation of transcription during field cancerization in non-small cell lung cancer.
- The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery.
- Comprehensive Analysis of Immune Cell Infiltration of m6a-Related lncRNA in Lung Squamous Cell Carcinoma and Construction of Relevant Prognostic Models.
- Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
- Ultrasound-Targeted Microbubble Destruction: Modulation in the Tumor Microenvironment and Application in Tumor Immunotherapy.
- TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.
- Reminiscence therapy involved care programs as an option to improve psychological disorders and patient satisfaction in elderly lung cancer patients: A randomized, controlled study.
- Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?".
- LncRNA MATN1-AS1 for Prediction of Prognosis in Osteosarcoma Patients and Its Cellular Function.
- AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer.
- Robot-assisted thoracic surgery for lung cancer patients with incomplete fissure.
- A Method to Identify Intersegmental Planes for Robotic-assisted Anatomic Segmentectomy Without Waiting.
- Serum tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-17 relate to anxiety and depression risks to some extent in non-small cell lung cancer survivor.
- A novel protein ubiquitination-related five-gene signature predicts overall survival in patients with lung adenocarcinoma.
- Potential role of glucosamine-phosphate N-acetyltransferase 1 in the development of lung adenocarcinoma.
- Single-cell RNA Sequencing Analysis Identifies Key Genes in Brain Metastasis from Lung Adenocarcinoma.
- CLEC12B suppresses lung cancer progression by inducing SHP-1 expression and inactivating the PI3K/AKT signaling pathway.
- Response to Letter to the Editor Titled "Intrathecal Pemetrexed: Another Potential Treatment Modality for TKI-Failed Leptomeningeal Metastases?".
- Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique
- Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
- Hospital anxiety and depression scale exhibits good consistency but shorter assessment time than Zung self-rating anxiety/depression scale for evaluating anxiety/depression in non-small cell lung cancer.
- Mechanism of tumor‑derived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1.
- Reminiscence therapy-based care program relieves anxiety, depression, and improves quality of life in post-operational non-small cell lung cancer patients.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status5
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Cancer Genome Atlas of China:Lung Cancer
Cancer
Pancreatic cancer
胰腺癌Led 11 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Harbin for pancreatic cancer192 hospitals in China for pancreatic cancer
No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led11
- Exosomal Non-Coding RNAs in Pancreatic Cancer: From Mechanisms to Clinical Applications.
- PSMD14 Transcriptionally Activated by MEF2A Promotes Pancreatic Cancer Development by Upregulating SPON2 Expression.
- A rare coexistence of solid pseudopapillary pancreatic tumor and papillary thyroid carcinoma arising from the pyramidal lobe: A rare case report.
- Circular RNAs in pancreatic cancer progression.
- Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.
- Exosomal miRNAs in the microenvironment of pancreatic cancer.
- Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy.
- Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase.
- Transcriptional ITPR3 as potential targets and biomarkers for human pancreatic cancer.
- Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.
- An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling.
All its trials on ClinicalTrials.gov, any status1
Cancer
Breast cancer
乳腺癌Led 48 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Harbin for breast cancer219 hospitals in China for breast cancer
No open trial on breast cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led48
- Developing and Evaluating a Nomogram Model Predicting Axillary Lymph Node Metastasis of Triple-Negative Breast Cancer Based on Multimodal Imaging Characteristics.
- N4-Acetylcytidine-Mediated CD2BP2-DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression.
- Differentiating triple-negative breast cancer and atypical fibroadenomas using an ultrasound-based radiomics nomogram.
- Prediction model for assessing HER2 status patient with invasive ductal carcinoma based on clinical parameters and ultrasound features: a dual-center study.
- Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2-positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study.
- Prediction of HER2-Low Breast Cancer via Multimodal Ultrasound Imaging.
- Lnc-TPT1-AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression.
- FTO promotes the progression of triple-negative breast cancer by regulating the m6A methylation of NFKBIE.
- Deep Learning for Distinguishing Mucinous Breast Carcinoma From Fibroadenoma on Ultrasound.
- Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3/Caspase-1/GSDMD signaling in human breast cancer cells.
- Application of Contrast-Enhanced Ultrasound Parameters of Metastatic Axillary Lymph Nodes in Breast Cancer Patients in Predicting the Efficacy of Neoadjuvant Chemotherapy in Early Stage.
- Association between albumin-related inflammatory biomarkers and breast cancer risk: A secondary analysis of NHANES 1998-2018.
- Correlation Between the Prognostic Nutritional Index and Breast Cancer in U.S. Adults: NHANES 2001-2018.
- Identification of a super enhancer associated gene signature for the prognosis prediction and regulatory mechanism exploration in breast cancer.
- Development of a Nomogram-Integrated Model Incorporating Intra-tumoral and Peri-tumoral Ultrasound Radiomics Alongside Clinical Parameters for the Prediction of Histological Grading in Invasive Breast Cancer.
- A Mammography-Based Radiomic Nomogram for Predicting Malignancy in Breast Suspicious Microcalcifications.
- Radiomic Nomogram for Predicting Axillary Lymph Node Metastasis in Patients with Breast Cancer.
- Breast cancer clinical outcomes and tumor immune microenvironment: cross-dialogue of multiple epigenetic modification profiles.
- Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.
- Circular RNAs in Breast Cancer: An Update.
- Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.
- Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.
- Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
- Associated factors leading to misdiagnosis of a combined diagnostic model of different types of strain imaging and conventional ultrasound in evaluation of breast lesions: Selection strategy for using different types of strain imaging in ev
- CHST4 associates with high-abundance immune infiltration in hormone receptor-positive breast cancer.
- Ultrasound-based radiomics nomogram for predicting axillary lymph node metastasis in early-stage breast cancer.
- Clinical Radiologic Analysis of 2964 Papillary Breast Lesions.
- Inhibition of Lymphangiogenesis: A Protective Role of microRNA 146a-5p in Breast Cancer.
- A Model Combining Conventional Ultrasound Characteristics, Strain Elastography and Clinicopathological Features to Predict Ki-67 Expression in Small Breast Cancer.
- Comparison of breast-conserving surgery without radiotherapy and mastectomy in the treatment of elderly patients with early breast cancer: A PSM and SEER database study.
- Inhibition of lncRNA PCAT19 promotes breast cancer proliferation.
- Silencing MFHAS1 Induces Pyroptosis via the JNK-activated NF-κB/Caspase1/ GSDMD Signal Axis in Breast Cancer.
- Deep learning-based classification of breast lesions using dynamic ultrasound video.
- Establishment and validation of an ultrasound-based nomogram with risk stratification for short disease-free survival in breast cancer.
- Radiogenomic analysis of prediction HER2 status in breast cancer by linking ultrasound radiomic feature module with biological functions.
- The Application of Mixed Reality to Sentinel Lymph Node Biopsy in Breast Cancer.
- Intercellular Communication Reveals Therapeutic Potential of Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer.
- Different precompression does not reduce the diagnostic value of virtual touch tissue imaging and quantification (VTIQ) in breast lesions, especially for the ratio of the shear wave velocity between lesions and surrounding tissues.
- Assessing Whether Morphological Changes in Axillary Lymph Node Have Already Occurred Prior to Metastasis in Breast Cancer Patients by Ultrasound.
- Nomograms predicting recurrence in patients with triple negative breast cancer based on ultrasound and clinicopathological features.
- Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study.
- Identifying ultrasound features of positive expression of Ki67 and P53 in breast cancer using radiomics.
- Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
- YY1-mediated long non-coding RNA Kcnq1ot1 promotes the tumor progression by regulating PTEN via DNMT1 in triple negative breast cancer.
- IGF-1R Transported to the Cell Nuclei to Regulate the Proliferation of Breast Cancer Cells.
- Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer.
- Diagnostic and prognostic role of NR3C4 in breast cancer through a genomic network understanding.
- Models for Predicting Sentinel and Non-sentinel Lymph Nodes Based on Pre-operative Ultrasonic Breast Imaging to Optimize Axillary Strategies.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
- To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
- Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China
- Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
- Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy
Cancer
Glioma
胶质瘤Led 31 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Harbin for glioma187 hospitals in China for glioma
No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led31
- A bibliometric analysis of global research trends in autophagy and glioblastomas.
- Immunotherapeutic strategies targeting the PVR-TIGIT/CD96/CD226 signaling pathway in glioma treatment.
- MicroRNA strand ratio disarray promotes temozolomide resistance in glioblastoma.
- Analysis of the Mechanism Underlying Radiotherapy Resistance Caused by Oligodendroglia Cells in Glioblastoma by Applying the Single-cell RNA Sequencing Technology.
- Deciphering the carcinogenic role of benzo[a]pyrene in glioblastoma: Insights from network toxicology, single-cell transcriptomics, and Mendelian randomization.
- Ruxolitinib suppresses tumor growth in PTEN-deficient glioblastoma by inhibiting the STAT3-PDL1 axis-mediated the M2 polarization of macrophages.
- Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment.
- A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance.
- Integrating deep learning and radiomics for preoperative glioma grading using multi-center MRI data.
- LncRNA-Mediated TPI1 and PKM2 Promote Self-Renewal and Chemoresistance in GBM.
- EMP3 as a prognostic biomarker correlates with EMT in GBM.
- Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance.
- Identifying and validating necroptosis-associated features to predict clinical outcome and immunotherapy response in patients with glioblastoma.
- Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing.
- Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway.
- Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
- Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma.
- Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.
- Neutrophils: New Critical Regulators of Glioma.
- 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas.
- High expression of N-type calcium channel indicates a favorable prognosis in gliomas.
- Identification of COL1A1 associated with immune infiltration in brain lower grade glioma.
- FBXO31 suppresses lipogenesis and tumor progression in glioma by promoting ubiquitination and degradation of CD147.
- Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-Dependent Pyroptosis in Glioblastoma Multiforme.
- m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
- Glioblastoma Cell-Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance.
- Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
- Circular RNA circ_ABCB10 in cancer.
- Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
- Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
- Dihydroartemisinin prompts amplification of photodynamic therapy-induced reactive oxygen species to exhaust Na/H exchanger 1-mediated glioma cells invasion and migration.
Cancer
Osteosarcoma
骨肉瘤Led 12 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Harbin for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led12
- Cognitive-behavioral stress management program alleviates anxiety and depression in parents of adolescent patients with osteosarcoma.
- BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies.
- MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma.
- 9-O-monoethyl succinate berberine effectively blocks the PI3K/AKT signaling pathway by targeting Wnt5a protein in inhibiting osteosarcoma growth.
- Anticancer effect of crizotinib on osteosarcoma cells by targeting c-Met signaling pathway.
- PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.
- Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3.
- lncRNA DARS-AS1 Promoted Osteosarcoma Progression through Regulating miR-532-3p/CCR7.
- Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma.
- LncRNA MATN1-AS1 for Prediction of Prognosis in Osteosarcoma Patients and Its Cellular Function.
- ALKBH5 suppresses tumor progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.
- Blue LED causes autophagic cell death in human osteosarcoma by increasing ROS generation and dephosphorylating EGFR.
Earlier papers (2016–2020)12
- LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
- LncRNA-XIST promotes the oxidative stress-induced migration, invasion, and epithelial-to-mesenchymal transition of osteosarcoma cancer cells through miR-153-SNAI1 axis.
- Calcium-sensing receptor activating ERK1/2 and PI3K-Akt pathways to induce the proliferation of osteosarcoma cells.
- Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.
- The expression of Eps15 homology domain 1 is negatively correlated with disease-free survival and overall survival of osteosarcoma patients.
- Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma.
- Dopamine D1 receptors induce apoptosis of osteosarcoma cells via changes of MAPK pathway.
- CpG methylation patterns are associated with gene expression variation in osteosarcoma.
- Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.
- Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells.
- Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α.
- MicroRNA-145 expression in the plasma of patients with benign and malignant bone tumors and its effects on osteosarcoma cell proliferation and migration.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Harbin for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Harbin for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Harbin for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value.
- Expression of NEAT1 can be used as a predictor for Dex resistance in multiple myeloma patients.
- Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma.
- Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients.
- Dynamic monitoring of serum ferritin as an adverse prognostic biomarker in patients with multiple myeloma.
- Mechanism of exosomal miR-155 derived from bone marrow mesenchymal stem cells on stemness maintenance and drug resistance in myeloma cells.
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Lymphoma
淋巴瘤Led 2 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.05%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Harbin for lymphoma199 hospitals in China for lymphoma
No open trial on lymphoma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 1 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Harbin for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Myasthenia gravis
重症肌无力Led 8 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Harbin for myasthenia gravis89 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- IMPDH2 facilitates CD4+ T cell activation through AKT/mTOR pathway by upregulating SRPK1 in myasthenia gravis.
- Construction of ceRNA network mediated by circRNAs screening from microarray and identification of novel biomarkers for myasthenia gravis.
- FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis.
- LncRNA OIP5-AS1 modulates the proliferation and apoptosis of Jurkat cells by sponging miR-181c-5p to regulate IL-7 expression in myasthenia gravis.
- Application Prospect of Artificial Intelligence in Rehabilitation and Management of Myasthenia Gravis.
- Identification of the regulatory role of lncRNA HCG18 in myasthenia gravis by integrated bioinformatics and experimental analyses.
- Competitive endogenous RNA network and pathway-based analysis of LncRNA single-nucleotide polymorphism in myasthenia gravis.
- Construction of a TF-miRNA-gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Coronary heart disease
冠心病Led 52 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 1.0%.
3 hospitals in Harbin for coronary heart disease231 hospitals in China for coronary heart disease
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSingle-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06489119
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Harbin Medical University; 1 listed hospital as study siteChangchun, Harbin
- Enrolling by invitationA Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07416344
Age 40 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Harbin Medical UniversityHarbin
- RecruitingSingle vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07587099
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Haikou, Harbin, Jinan, Liaocheng, Nanchang, Qingdao, Urumqi
- RecruitingEfficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- Phase
- Phase 4
- Started
- 2025-11
- Posted
- Registry
- NCT07110415
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai
- Not yet recruitingOptimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Phase
- N/A
- Started
- 2021-09
- Posted
- Registry
- NCT04995159
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led52
- Mechanistic study of the effects of different dietary patterns on coronary plaque vulnerability via the dietary inflammatory index in patients with coronary heart disease: A structural equation modeling approach.
- A nomogram-based prediction model for motoric cognitive risk syndrome in patients with coronary artery disease: a cross-sectional study.
- Ambient temperature and coronary plaque rupture risk in STEMI: Insights from OCT analysis.
- Comparative outcomes of invasive versus conservative strategy in stable coronary artery disease patients: a risk-stratification-based hypothesis-generative study.
- Associations of Plasma Metabolite Phenylacetylglutamine on Coronary Plaque Characterization in Patients with ST-Segment Elevation Myocardial Infarction.
- Association Between the Uric Acid to High-Density Lipoprotein Cholesterol Ratio and Residual Risk for Coronary Artery Disease.
- Safety and Efficacy of Intravascular Lithotripsy System: A Prospective, Multicenter Clinical Trial (The VIGOUR Study).
- Long-Term Prognostic Implications of Non-Culprit Lesions in Patients Presenting With an Acute Myocardial Infarction: Is It the Angiographic Stenosis Severity or the Underlying High-Risk Morphology?
- Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.
- Impact of non-culprit lesion TCFA on adverse cardiovascular events in patients with diabetes mellitus who present with acute myocardial infarction.
- Type D personality as a risk factor for 3-year cardiovascular events in patients with coronary artery disease and their spouse: a prospective cohort study.
- Circular RNA hsa_circ_0124644 regulates apoptosis of endothelial cells in coronary artery disease.
- Surgical Repair of Ruptured Giant Coronary Artery Aneurysm and Pulmonary Artery Fistula.
- Carotid Intraplaque neovascularization correlates with coronary atherosclerotic plaque, vulnerability detected by intracoronary optical coherence tomography.
- Artificial intelligence driven plaque characterization and functional assessment from CCTA using OCT-based automation: A prospective study.
- Glycemic control and coronary plaque characteristics in patients with acute myocardial infarction.
- Quantitative flow ratio-based revascularization on clinical outcomes in multivessel disease STEMI patients with chronic kidney disease.
- Non-invasive imaging innovation: FFR-CT combined with plaque characterization, safeguarding your cardiac health.
- Angiographic Quantitative Flow Ratio-Guided Treatment of Patients With Physiologically Intermediate Coronary Lesions.
- Association of Circulating Phenylacetylglutamine With Multi-Vessel Coronary Disease Severity and Outcomes in ST-Segment-Elevation Myocardial Infarction.
- Higher oxidative balance score is associated with increased plaque stability in patients with coronary heart disease.
- Plaque Ruptures Are Related to High Plaque Stress and Strain Conditions: Direct Verification by Using In Vivo OCT Rupture Data and FSI Models.
- Revealing the molecular links between coronary heart disease and cognitive impairment: the role of aging-related genes and therapeutic potential of stellate ganglion block.
- A Bidirectional Mendelian Randomization Study of the Causal Association Between Ischemic Stroke, Coronary Heart Disease, and Hydrocephalus.
- Large-scale, comprehensive plasma metabolomic analyses reveal potential biomarkers for the diagnosis of early-stage coronary atherosclerosis.
- Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial.
- The effect of miR-223-3p on endothelial cells in coronary artery disease.
- CDKN2B-AS1 may act as miR-92a-3p sponge in coronary artery disease.
- Pancoronary plaque characteristics and clinical outcomes in acute coronary syndrome patients with cancer history.
- Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states.
- Combining metabolomics and OCT to reveal plasma metabolic profiling and biomarkers of plaque erosion and plaque rupture in STEMI patients.
- Clinical Characteristics and Prognosis of MINOCA Caused by Atherosclerotic and Nonatherosclerotic Mechanisms Assessed by OCT.
- Exosome-derived circ_0001785 delays atherogenesis through the ceRNA network mechanism of miR-513a-5p/TGFBR3.
- Identification of High-Risk Coronary Lesions by 3-Vessel Optical Coherence Tomography.
- High dietary inflammatory index is associated with decreased plaque stability in patients with coronary heart disease.
- Safety and effectiveness of nano composite hydrogel stent implantation in the treatment of coronary cardiovascular disease: A preclinical study.
- Relationship between stressful life events and coronary plaque vulnerability among patients with acute coronary syndrome: a moderated mediation model of psychological distress and physiological indices.
- Type D Personality as a Risk Factor for Adverse Outcome in Patients With Cardiovascular Disease: An Individual Patient-Data Meta-analysis.
- Characteristics of coronary artery ectasia and accompanying plaques: an optical coherence tomography study.
- Impact of nodular calcification in patients with acute coronary syndrome (ACS) treated with primary percutaneous coronary intervention (PCI).
- Predictors of Adverse Prognosis in Patients With Acute Coronary Syndrome Caused by Plaque Erosion With a Nonstent Strategy.
- The Potential Mediating Effects of Inflammation on the Association Between Type D Personality and Coronary Plaque Vulnerability in Patients With Coronary Artery Disease: An Optical Coherence Tomography Study.
- Optical Coherence Tomographic Features of Pancoronary Plaques in Patients With Acute Myocardial Infarction Caused by Layered Plaque Rupture Versus Layered Plaque Erosion.
- WeChat-based education and rehabilitation program in unprotected left main coronary artery disease patients after coronary artery bypass grafting: an effective approach in reducing anxiety, depression, loss to follow-up, and improving quali
- Is the effect of atorvastatin 60 mg on stabilization of lipid-rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging.
- Association of the age shock index with coronary plaque characteristics in ST-segment elevation myocardial infarction: A 3-vessel optical coherence tomography study.
- Optical coherence tomography and tailored treatment of in-stent restenosis.
- Diagnostic utility of circulating plasma microRNA-101a in severity of coronary heart disease.
- Longitudinal change and prognostic value of anxiety and depression in coronary heart disease patients.
- Association between food and nutrients intakes and coronary plaque vulnerability in patients with coronary heart disease: An optical coherence tomography study.
- Relationship between non-culprit lesion plaque characteristics changes and in-stent neoatherosclerosis formation: 1-year follow-up optical coherence tomography study.
- Assessment of Left Ventricular Global Myocardial Work in Patients With Different Degrees of Coronary Artery Stenosis by Pressure-Strain Loops Analysis.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status20
- A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
- Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
- The AIPLAQUE Study: An Artificial Intelligence-based Prospective Study to Analyze PLAQUE Using CCTA
- Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)
- Primary FIbrinolysis and Secondary STenting Versus immEdiate Stenting in ST-segment Elevation Myocardial Infarction
- PANOVISION: Feasibility and Safety of Hybrid IVUS-OCT System
- Peripheral Vascular Disease and Coronary Artery Disease
- Clinical Presentations Before AMI Onset and Coronary Atherosclerosis
- Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns
- Assessment of Surface Coverage of Two Types of Drug-eluting Stent in Diabetes Mellitus and Non-Diabetes Mellitus
- Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT
- Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT) Combined With Intravascular Ultrasound (IVUS)
- Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- CorVad Percutaneous Ventricular Assist System Study
- Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
- PROMUS PREMIER™ China Post-Approval Study
- Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent
- Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease
Other diseases
Congenital heart disease
先天性心脏病Led 4 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Harbin for congenital heart disease207 hospitals in China for congenital heart disease
No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led4
- Identification of immune-related signatures and pathogenesis differences between thoracic aortic aneurysm patients with bicuspid versus tricuspid valves via weighted gene co-expression network analysis.
- LncRNA DiGeorge syndrome critical region gene 5: A crucial regulator in malignant tumors.
- Right atrial papillary fibroelastoma arising from the Chiari network detected by echocardiography: a case report and literature review.
- Risk factors and predictors of QTc prolongation in critically ill Chinese patients.
Other diseases
Hepatic echinococcosis
肝包虫病Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Harbin for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 11 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Harbin for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led11
- SCPEP1+ basal cells are associated with the remodeling of oxidative stress signaling networks in idiopathic pulmonary fibrosis.
- Orderly Regulation of Macrophages and Fibroblasts by Axl in Bleomycin-Induced Pulmonary Fibrosis in Mice.
- YBX1 regulation of alveolar type II epithelial cells in idiopathic pulmonary fibrosis: mechanistic insights and small-molecule drug screening.
- Common biomarkers of idiopathic pulmonary fibrosis and systemic sclerosis based on WGCNA and machine learning.
- Rbms1 promotes pulmonary fibrosis by stabilising Sumo2 mRNA to facilitate Smad4-SUMOylation and fibroblast activation.
- Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study.
- Identification of cuproptosis-related diagnostic biomarkers in idiopathic pulmonary fibrosis.
- Bioinformatics approach to identify the hub gene associated with COVID-19 and idiopathic pulmonary fibrosis.
- An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis.
- S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis.
- CD247, a Potential T Cell-Derived Disease Severity and Prognostic Biomarker in Patients With Idiopathic Pulmonary Fibrosis.
Earlier papers (2016–2020)1
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Harbin for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Harbin for Fabry disease80 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Harbin for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Harbin for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Mitochondrial morphological aberrations and redistribution in podocytes with glomerular diseases.
- Identification of miRNA-mRNA network and immune-related gene signatures in IgA nephropathy by integrated bioinformatics analysis.
- LncRNA PTTG3P induced aberrant glycosylated IgA1 production and B cell growth in IgA nephropathy.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Harbin for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Harbin for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Getting in touch
Name card to show staff or a driver
哈尔滨医科大学附属第二医院
Second Affiliated Hospital of Harbin Medical University
哈尔滨
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Second Affiliated Hospital of Harbin Medical University Harbin; second affiliated hospital of Harbin Medical University